Dose–response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia

References

• Lyrica prescribing information. 2013. Pfizer Inc. cited 2016 Feb 2. Available from http://labeling.pfizer.com/ShowLabeling.aspx?id=561
   Google Scholar
• LYRICA® EU product information. 2015. Pfizer Inc. cited 2016 Feb 16. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003880/WC500166172.pdf
   Google Scholar
• Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758–1765.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68:900–918.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167–184.
   PubMed Web of Science ®Google Scholar
• Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum. 2011;41:335–345.e6.
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448–1454.
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076. DOI: 10.1002/14651858.CD007076.pub2
   PubMed Web of Science ®Google Scholar
• Byon W, Ouellet D, Chew M, et al. Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change. J Clin Pharmacol. 2010;50:803–815.
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–2110.
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253–260.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–638.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274–1283.
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Gálvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35.
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP Jr., et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22:375–384.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805.
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Study 1008-040. Data on file.
   Google Scholar
• Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203–213.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Study 1008-173. Data on file.
   Google Scholar
• Pfizer Inc. Study 1008-030. Data on file.
   Google Scholar
• Pfizer Inc. Study 1008-132. Data on file.
   Google Scholar
• Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172.
   PubMed Web of Science ®Google Scholar
• Thomas N, Sweeney K, Somayahi V. Meta-analysis of clinical dose–response in a large drug development portfolio. Stat Biopharm Res. 2014;6:302–317.
   Web of Science ®Google Scholar
• Källén A. Computational pharmacokinetics. Boca Raton, Florida: CRC; 2007.
   Google Scholar
• Johnson P, Becker L, Halpern R, et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33:35–44.
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky A, Zlateva G, et al. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care. 2010;16:S144–53.
   PubMed Web of Science ®Google Scholar
• Sun P, Zhao Y, Zhao Z, et al. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Curr Med Res Opin. 2011;27:1793–1801.
   PubMed Web of Science ®Google Scholar
• Yang M, Qian C, Liu Y. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States. Pain Med. 2015;16:2075–2083.
   PubMed Web of Science ®Google Scholar
• Sanchez RJ, Mardekian J, Clair AG, et al. Therapeutic and subtherapeutic dosing of pregabalin: medication adherence, healthcare resource utilization, and costs. Am J Pharm Benefits. 2012;4:158–164.
   Google Scholar
• Pfizer Inc. Mu sigma pregabalin dosing by indication and strength. Truven Health Analytics Claims Data. Data on file; 2015 Feb.
   Google Scholar
• Parsons B, Emir B, Clair A. Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin. J Pain Res. 2015;8:303–309.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2015;15:47–57.
   PubMed Web of Science ®Google Scholar
• Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin. 2012;28:1027–1037.
   PubMed Web of Science ®Google Scholar
• Frame B, Beal SL, Miller R, et al. Mixed effects modeling of weight change associated with placebo and pregabalin administration. J Pharmacokinet Pharmacodyn. 2007;34:753–770.
   PubMed Web of Science ®Google Scholar
• Juhn MS, Parsons B, Varvara R, et al. Pregabalin for painful diabetic peripheral neuropathy: strategies for dosing, monotherapy vs. combination therapy, treatment-refractory patients, and adverse events. Curr Med Res Opin. 2015;31:1017–1026.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Farmer MV, Palmer RH, et al. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis. 2013;5:113–126.
   PubMedGoogle Scholar
• Gilron I, Chaparro LE, Tu D, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016;157:1532–1540.
   PubMed Web of Science ®Google Scholar
• Mu Y, Liu X, Li Q, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized, placebo-controlled trial. J Diabetes. 2017. DOI: 10.1111/1753-0407.12585. [Epub ahead of print].
   Web of Science ®Google Scholar
• Moon DE, Lee DI, Lee SC, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32:2370–2385.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chen H, Xi L, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin for postherpetic neuralgia in a population of Chinese patients. Pain Pract. 2017;17:62–69.
   PubMed Web of Science ®Google Scholar
• Ohta H, Oka H, Usui C, et al. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14:R217.
   PubMed Web of Science ®Google Scholar